Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

• ClinicalTrials.gov Identifier: NCT02396342
• Recruitment Status: Active, not recruiting
• First Posted: March 24, 2015
• Last Update Posted: January 7, 2021
• Sponsor: UniQure Biopharma B.V.
• Information provided by (Responsible Party): UniQure Biopharma B.V.

Tracking Information

• First Submitted Date: March 4, 2015
• First Posted Date: March 24, 2015
• Last Update Posted Date: January 7, 2021
• Actual Study Start Date: June 10, 2015
• Estimated Primary Completion Date: May 2021 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: March 18, 2015): Adverse Events [ Time Frame: Five years ]
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: March 18, 2015)

• FIX-replacement-therapy-free FIX activity [ Time Frame: Five years ]
• Bleeding rate [ Time Frame: Five years ]
• Total consumption of FIX replacement therapy [ Time Frame: Five years ]
• Short Form-36 Quality of Life scores [ Time Frame: Five years ]
• Vector DNA in semen, blood, saliva, nasal secretions, urine and faeces [ Time Frame: Up to five years but maximally until the date that 3 consecutive samples are negative ]
• Neutralizing antibodies to AAV5 [ Time Frame: Five years ]
• Total (IgM and IgG) antibodies to AAV5 [ Time Frame: Five years ]
• AAV5 capsid-specific T cells [ Time Frame: 26 weeks ]
• Antibodies to FIX [ Time Frame: Five years ]
• FIX inhibitors [ Time Frame: Five years ]
• Inflammatory markers: Interleukin(IL)-1β, IL-2, IL-6, Interferon γ, Monocyte Chemotactic Protein-1 [ Time Frame: 18 weeks ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
• Official Title: A Phase I/II, Open-label, Uncontrolled, Single-dose, Dose-ascending, Multi-centre Trial Investigating an Adeno-associated Viral Vector Containing a Codon-optimized Human Factor IX Gene (AAV5-hFIX) Administered to Adult Patients With Severe or Moderately Severe Hemophilia B
• Brief Summary: This study evaluates how safe gene therapy treatment with AAV5-hFIX is in adult patients with severe or moderately severe hemophilia B and severe bleeding type.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Hemophilia B

Intervention

Genetic: AAV5-hFIX

AAV5hFIX gene therapy

Other Name: AAV5 containing a codon-optimized human factor IX gene

Study Arms

• Experimental: Cohort 1
  AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
  Intervention: Genetic: AAV5-hFIX
• Experimental: Cohort 2
  AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
  Intervention: Genetic: AAV5-hFIX

• Publications *: Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwäble J, Bonig H, Seifried E, Cattaneo F, Meyer C, Leebeek FWG. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018 Mar 1;131(9):1022-1031. doi: 10.1182/blood-2017-09-804419. Epub 2017 Dec 15.

Recruitment Information

• Recruitment Status: Active, not recruiting
• Estimated Enrollment (submitted: March 18, 2015): 10
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: May 2021
• Estimated Primary Completion Date: May 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Male
2. Age ≥ 18 years

3. Patients with congenital hemophilia B classified as one of the following:

   • Known severe FIX deficiency with plasma FIX activity level < 1% and a severe bleeding phenotype defined by one of the following:

     • Currently on prophylactic FIX replacement therapy for a history of bleeding
     • Currently on on-demand therapy with a current or past history of frequent bleeding defined as four or more bleeding episodes in the last 12 months or chronic hemophilic arthropathy (pain, joint destruction, and loss of range of motion) in one or more joints

   • Known moderately severe FIX deficiency with plasma FIX activity level between ≥ 1% and ≤ 2% and a severe bleeding phenotype defined by one of the following:

     • Currently on prophylactic FIX replacement therapy for a history of bleeding
     • Currently on on-demand therapy with a current or past history of frequent bleeding defined as four or more bleeding episodes in the last 12 months or chronic hemophilic arthropathy (pain, joint destruction, and loss of range of motion) in one or more joints
4. More than 150 previous exposure days of treatment with FIX protein.
5. Acceptance to use a condom during sexual intercourse in the period from Investigational Medicinal Product (IMP) administration until AAV5 has been cleared from semen, as evidenced by the central laboratory from negative analysis results for at least 3 consecutively collected semen samples (this criterion is applicable also for subjects who are surgically sterilized)
6. Following receipt of verbal and written information about the trial, the subject has provided signed informed consent before any trial related activity is carried out.

Exclusion Criteria:

1. History of FIX inhibitors measured to be ≥ 0.6 Bethesda Units (BU)/mL
2. FIX inhibitors ≥ 0.6 BU/mL at Visit 1 (measured by the local laboratory)
3. Neutralizing antibodies against AAV5 at Visit 1 (measured by the central laboratory)

4. Visit 1 laboratory values (measured by the central laboratory):

   • alanine aminotransferase > 2 times upper normal limit
   • aspartate aminotransferase > 2 times upper normal limit
   • total bilirubin > 2 times upper normal limit
   • alkaline phosphatase > 2 times upper normal limit
   • creatinine > 1.5 times upper normal limit
5. Positive HIV serological test at Visit 1, not controlled with anti-viral therapy as shown by cluster of differentiation 4+ counts ≤ 200 per μL or by a viral load of >200 copies per mL (measured by the central laboratory)
6. Active infection with Hepatitis B or C virus as reflected by Hepatitis B Surface Antigen (HBsAg), Hepatitis B extracellular Antigen (HBeAg), Hepatitis B Virus DeoxyriboNucleic Acid (HBV DNA) or Hepatitis C Virus RiboNucleic Acid (HCV RNA) positivity, respectively, at Visit 1 (measured by the central laboratory).
7. History of Hepatitis B or C exposure, currently controlled by antiviral therapy
8. Any coagulation disorder other than hemophilia B
9. Thrombocytopenia, defined as a platelet count below 50 × 10E9 / L, at Visit 1 (measured by the central laboratory)
10. Body mass index < 16 or ≥ 35 kg/m2
11. Planned surgery for the initial 6 months after IMP administration in this trial
12. Previous arterial or venous thrombotic event (e.g. acute myocardial infarction, cerebrovascular disease and venous thrombosis)
13. Active severe infection or any other significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease, alcoholism, drug dependency or any other psychological disorder evaluated by the investigator to interfere with adherence to the protocol procedures or with the degree of tolerance to the IMP
14. Known significant medical condition including disseminated intravascular coagulation, fibrinolysis and liver fibrosis which, in the opinion of the investigator, may confound, contraindicate or limit the interpretation of either safety or efficacy data
15. Known history of an allergic reaction or anaphylaxis to FIX products
16. Known uncontrolled allergic conditions or allergy/hypersensitivity to any component of the IMP excipients
17. Previous gene therapy treatment and/or previous participation in a gene therapy clinical trial
18. Receipt of an experimental agent within 60 days prior to Visit 1
19. Current participation or anticipated participation within one year after IMP administration in this trial in any other interventional clinical trial involving drugs or devices.

Sex/Gender

• Sexes Eligible for Study: Male

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Denmark, Germany, Netherlands
• Removed Location Countries: Italy

Administrative Information

• NCT Number: NCT02396342
• Other Study ID Numbers: CT-AMT-060-01
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Responsible Party: UniQure Biopharma B.V.
• Study Sponsor: UniQure Biopharma B.V.
• Collaborators: Not Provided

Investigators

• Study Director: uniQure Clinical Trials; UniQure Biopharma B.V.

• PRS Account: UniQure Biopharma B.V.
• Verification Date: January 2021